



AIBMR Life Sciences, Inc.

July 21, 2020

Susan Carlson, PhD
Division Director
Division of Biotechnology and GRAS Notice Review
Office of Food Additive Safety (HFS-200)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
Department of Health and Human Services
5001 Campus Drive
College Park, MD 20740



Dear Dr. Carlson:

In accordance with regulation 21 CFR Part 170 Subpart E (Generally Recognized as Safe (GRAS) Notice), on behalf of Danisco USA, Inc. (the notifier), the undersigned, Jessica Gruber, submits, for FDA review, the enclosed notice that *Bacillus subtilis* Bss-19 is GRAS under the conditions of its intended use in foods.

Should you have any questions or concerns regarding this notice, please contact me at 253-286-2888 or jessica@aibmr.com.

Sincerely,



Jessica Gruber, ND (agent of the notifier)
Scientific and Regulatory Consultant
AIBMR Life Sciences, Inc. ("AIBMR")

September 11, 2020

Dr. Carlson and staff,

To prevent any potential confusion, this submission replaces one that should have arrived at your office on July 29, 2020, but apparently was lost by FedEx.

If you did indeed receive that first shipment, please disregard this duplicate.

Thank you!

Jared

Jared Douglas Brodin
Director of Information Services
AIBMR Life Sciences, Inc.

**Notice to US Food and Drug Administration of the
Conclusion that the Intended Use of Bss-19 is
Generally Recognized as Safe**

Submitted by the Notifier:

Danisco USA, Inc.
DuPont Nutrition & Biosciences
Four New Century Parkway
New Century, Kansas 66031

Prepared by the Agent of the Notifier:

AIBMR Life Sciences, Inc
1425 Broadway, Suite 458
Seattle WA 98122

July 21, 2020



Table of Contents

Part 1: Signed Statements and Certification	6
1.1 Submission of GRAS Notice	6
1.2 Name and Address of the Notifier and Agent of the Notifier	6
1.3 Name of the Substance.....	6
1.4 Intended Conditions of Use.....	6
1.5 Statutory Basis for GRAS Conclusion.....	7
1.6 Not Subject to Premarket approval	7
1.7 Data and Information Availability Statement	7
1.8 Exemption from Disclosure under the Freedom of Information Act.....	7
1.9 Certification of Completion	8
Part 2: Identity, Method of Manufacture, Specifications, and Physical or Technical Effect.....	9
2.1 Identification	9
2.1.1 Taxonomy of Bss-19	9
2.1.2 Genetic Identification of Bss-19.....	9
2.2 Manufacturing	10
2.2.1 Good Manufacturing Practice.....	10
2.2.2 Raw Materials.....	10
2.2.3 Manufacturing Narrative and Flowchart	10
2.3 Specifications	14
2.3.1 Batch Analysis.....	15
2.3.2 Residual Pesticide Analysis.....	16
2.3.3 Shelf–Life Stability	16
2.4 Antibiotic Resistance	16
2.5 Genomic Analysis for Virulence and Pathogenicity.....	18
2.6 Resistance to Gastric Acidity and Bile Salts.....	18
2.7 Hemolysis.....	19
2.8 Biogenic Amine Formation.....	20
2.9 D(-)/L(+)-Lactic Acid Production.....	20
2.10 Carbohydrate Analysis	21
2.11 Physical or Technical Effect	22
Part 3: Intended Use and Dietary Exposure.....	23
Part 4: Self-limiting Levels of Use	24
Part 5: Experience Based on Common Use in Food Prior to 1958.....	25
Part 6: Narrative.....	26
6.1 History of Consumption.....	26
6.2 Regulatory Opinions	26
6.2.1 Europe.....	26
6.2.2 United States.....	27
6.2.3 Canada	28
6.3 Safety Information	28



6.3.1 Toxicological Studies on <i>B. subtilis</i> strains.....	29
6.3.2. Unpublished Acute Toxicity Study on <i>B. subtilis</i> Bss-19	30
6.3.3. Human Studies.....	31
6.3.4 Opportunistic Infections	32
6.4 Allergenicity.....	32
6.5 Past Sales and Reported Adverse Events	33
6.6 Basis for the GRAS Conclusion.....	33
6.6.1 Data and Information that Establish Safety	33
6.6.2 Data and Information that are Corroborative of Safety	34
6.6.3 General Recognition	35
6.6.4 Data and Information that are Inconsistent with the GRAS Conclusion.....	35
6.6.5 Information that is Exempt from Disclosure under FOIA.....	35
Part 7: Supporting Data and Information.....	36
7.1 Data and Information that are <i>not</i> Generally Available	36
7.2 References that <i>are</i> Generally Available	36



Figures and Tables

Table 1. Genomic Average Nucleotide Identity Comparison of Bss-19 to Other Relevant Strains.....	10
Figure 1. Manufacturing Flowchart.....	14
Table 2. Bss-19 Specifications	14
Table 3. Bss-19 Batch Analyses.....	15
Table 4. Bss-19 Phenotypic Resistance to Antibiotics Results	17
Table 5. Acid Tolerance and Bile Tolerance of Bss-19 in its Vegetative State and Spore Form	19
Table 6. Sugar Fermentation Capacity (API 50 CH) of Bss-19	21
Table 7. FDA GRAS Notifications that Include <i>B. subtilis</i> Strains	27



Part 1: Signed Statements and Certification

1.1 Submission of GRAS Notice

Danisco USA, Inc. (the notifier), an affiliate of DuPont Nutrition & Biosciences (hereafter referred to as DuPont) is submitting a new GRAS notice in accordance with 21 CFR Part 170, Subpart E, regarding the conclusion that *Bacillus subtilis* Bss-19 is Generally Recognized as Safe (GRAS) for its intended use, consistent with section 201(s) of the Federal Food, Drug and Cosmetic Act.

1.2 Name and Address of the Notifier and Agent of the Notifier

Notifier

Elizabeth McCartney
Regulatory Affairs Specialist
Danisco USA, Inc.
DuPont Health & Biosciences
3329 Agriculture Drive
Madison, Wisconsin 53716
Tel: (608) 216-6307; Fax: (608) 395-2630
elizabeth.mccartney@dupont.com

Agent of the Notifier

Jessica Gruber, ND
Scientific and Regulatory Consultant
AIBMR Life Sciences, Inc.
1425 Broadway, Suite 458
Seattle, WA 98122
Tel: (253) 286-2888
jessica@aibmr.com

1.3 Name of the Substance

The name of the substance is *Bacillus subtilis* Bss-19.

1.4 Intended Conditions of Use

B. subtilis Bss-19 (hereafter referred to as Bss-19) is intended to be used as an ingredient added to foods where standards of identity do not preclude such use. It is not intended to be added to infant formula, or any products that would require



additional regulatory review by USDA. The intended addition level to foods is up to 1×10^{10} CFU per serving.

1.5 Statutory Basis for GRAS Conclusion

The conclusion of GRAS status of Bss-19 for its intended conditions of use, stated in Part 1.4 of this notice, has been made based on scientific procedures.

1.6 Not Subject to Premarket approval

We have concluded that Bss-19 is GRAS for its intended conditions of use, stated in Part 1.4 of this notice, and, therefore, such use of Bss-19 is not subject to the premarket approval requirements of the Federal Food, Drug, and Cosmetic Act.

1.7 Data and Information Availability Statement

The data and information that serve as the basis for this GRAS conclusion will be available for review and copying during customary business hours at the office of Elizabeth McCartney (DuPont Health & Biosciences, 3329 Agriculture Drive Madison, Wisconsin 53716), or will be sent to FDA upon request.

1.8 Exemption from Disclosure under the Freedom of Information Act

None of the data and information in Parts 2 through 7 of this GRAS notice are considered exempt from disclosure under the Freedom of Information Act (FOIA) as trade secret or commercial or financial information that is privileged or confidential.



1.9 Certification of Completion

We hereby certify that, to the best of our knowledge, this GRAS notice is a complete, representative, and balanced submission that includes unfavorable information, as well as favorable information, known to us and pertinent to the evaluation of the safety and GRAS status of the use of Bss-19.

(b) (4)

A large rectangular area of the document is redacted with a solid grey fill, obscuring the signature and name of the notifier.

21 July 2020

Elizabeth McCartney
Regulatory Affairs Specialist
Notifier

Date



Part 2: Identity, Method of Manufacture, Specifications, and Physical or Technical Effect

2.1 Identification

B. subtilis is a gram-positive, rod-shaped, endospore-forming bacterium found in the soil, on plants, in water sources, and in the gastrointestinal tract of humans.^{1,2} It has several flagella and is highly motile.¹ While there are members of the *Bacillus* genus that are known to have toxic effects in humans and animals via production of toxins (e.g. *B. anthracis*, *B. cereus*), *B. subtilis* has a long history of safe use for human consumption as will be detailed in Part 6.³

Dupont's Bss-19 is also known as *B. subtilis* BS7711. Additionally, DGCC12972 is used as the internal identification within the DuPont Global Culture Collection.

2.1.1 Taxonomy of Bss-19

Dupont's *B. subtilis* inaquosorum strain Bss-19 has been identified according to standard taxonomic guidelines. The taxonomic lineage of the strain is:

Kingdom: Bacteria

Phylum: Firmicutes

Class: Bacilli

Family: Bacillales

Genus: *Bacillus*

Species: *Bacillus subtilis*

Strain: inaquosorum strain Bss-19

2.1.2 Genetic Identification of Bss-19

The whole genome of Bss-19 was sequenced, assembled, and included a single 16S rRNA gene copy. When compared to publicly available sequences, the 16S rRNA copy of Bss-19 was found to be most closely related to the type strain *B. subtilis* subspecies inaquosorum KCTC 13429 (99.93% identical).

Whole genome sequencing and assembly of Bss-19 revealed seven single nucleotide variations between the assemblies when compared to publicly available *B. subtilis* inaquosorum strain DE111 sequence. Four of these changes were confirmed by PCR. Two of the single nucleotide variations resulted in amino acid changes indicating that these strains do not have identical genomes.

Genomic average nucleotide identity (ANI) comparison of the whole draft genome sequence of strain Bss-19 to relevant, closely related strains: DE111, KCTC 13429 (the type strain for the subspecies inaquosorum), and strain 168 (the type strain for



the closely related subspecies *B. subtilis* subsp. *subtilis*) was performed. ANI values above 95% are considered representatives of members of the same species. ANI calculations, shown in Table 1, indicate Bss-19 is of the same species as DE111 and KCTC 13429; but that inaquosorum may be considered a separate species from the subtilis subspecies. DuPont states that ANI is calculated using two factors to produce a third. Overall percent identity of the portions of the sequence that align (ANI) and fraction of the two genomes which do align (coverage) are multiplied to produce the Hadamard product. The Hadamard product is usually a smaller percent identity than the initially reported percent identity unless coverage is complete for both genomes.

Table 1. Genomic Average Nucleotide Identity Comparison of Bss-19 to Other Relevant Strains

	<i>B. subtilis</i> inaquosorum		<i>B. subtilis</i> subtilis
	strain DE111	strain KCTC 13429	strain 168
Coverage	99.84%	93.86%	84.52%
Percent identity (ANI)	99.98%	98.83%	93.00%
Hadamard product	99.83%	92.77%	78.61%

DuPont states that whole genome sequences of Bss-19, DE111, and KCTC 13429 aligned using the Mauve Progressive Alignment⁴ tool indicate strong conservation between Bss-19 and DE111, but KCTC 13429 appears to contain unique regions ranging in size from 2 to~40 kb.

2.2 Manufacturing

2.2.1 Good Manufacturing Practice

All production steps of Bss-19 are consistent with current Good Manufacturing Practice (cGMP) guidelines in an FDA regulated and inspected facility.

2.2.2 Raw Materials

Raw materials used in the production of DuPont’s Bss-19 are of appropriate food grade and are suitable to the application to produce the final food grade product.

2.2.3 Manufacturing Narrative and Flowchart

Master Seed

The source organism used is *Bacillus subtilis* Bss-19.



DuPont takes great care to ensure the quality of bacteria fermentation products. These quality control processes begin with the identification, storage, and handling of the bacteria seed stocks.

A Master Seed repository is maintained for each of the bacterial strains at the DuPont Global Culture Collection (DGCC) in Niebüll, Germany. The repository is a collection of purified, tested, and qualified Master Seed stocks derived from single strain isolates stored at -180°C in liquid nitrogen to maintain long term cell viability. Each seed lot in the culture bank is fully characterized to ensure the identity of the seed strains.

Whole genome sequencing is conducted to establish the identity of each bacteria to the genus, species, and strain level prior to preservation. The microbiological quality of the Master Seeds is determined by testing for microbiological contamination at the DGCC. These identity and purity specifications are absolute acceptance criteria for the Master Seeds. If a Master Seed vial lot fails any of the required tests, the lot is placed on Quality Control (QC) hold to prohibit use and the lot is subsequently destroyed.

Working seed

Working seeds are prepared under controlled conditions from master seed stock maintaining effective acceptance criteria at DGCC. All Working Seeds are prepared under controlled conditions from Master Seed stock meeting established acceptance criteria and each new lot of Working Seeds is held in quarantine pending QC testing (strain identity and purity as described for the Master Seeds) and release. If the Working Seed vial lot fails any of the required tests, the lot is placed on QC hold and destroyed. Qualified, tested Working Seed stocks are stored at -80°C until used in production fermentation.

The use of tandem Master and Working seed inventories reduces the risk of genetic drift over time due to excessive sub-culturing of strains and ensures the integrity of the strain collection. All steps in the preparation of Master and Working seed are documented in a specified database, allowing traceability of every seed preparation down to each single batch of raw material used.

Fermentation process

The fermentation begins by withdrawing one of the working seed vials and scaling-up via a series of fermentations until a commercial size batch is complete.

The fermentation media contains a buffer system to minimize pH shifts. The pH profile for each batch is monitored against a standard to ensure repeatability. The pH in the fermenter is monitored on digital display and on recording charts. By consulting these charts, the growth and sporulation characteristic of a given fermentation can be determined.



After fermentation is complete, an additional aeration step is performed in the fermenter. Airflow is increased and back pressure decreased for a specified amount of time. The fermenter is then normally cooled to stop the fermentation at a specified time. Cooled fermentate is pumped through a continuous flow centrifuge and the bacterial spores are concentrated. The bacterial spore concentrate is pumped to a spray dryer where it is atomized and dried. After spray drying, the bacterial spore concentrate is bulk packaged with lot control and traceability, then stored until QC release against specified criteria.

The fermentation production process is a closed system with no product exposure from seed inoculation to cell harvest. Prior to each fermentation batch, all mixing tanks, lines, fermenter, centrifuge, and spray dryer are cleaned via automated clean-in-place systems. Systems are then either steamed or chemically sanitized prior to product contact.

Packaging

Bulk packaging of the product is carried out in a controlled environment within the DuPont Rochester facility.

HEPA filter is used in the packaging room for high performance as the final filter for particulate removal when clean air is required.

Final packages are heat sealed before passing through a metal detection x-ray system.

Quality Systems

The DuPont Rochester plant has fully implemented HACCP plans, Standard Operating Procedures and Quality Control programs to ensure the quality of each product. A quality control laboratory is maintained on site. Quality control personnel are qualified by training and experience to test products and to release product based on specifications. In addition, a third-party approved laboratory with ISO 17025 certification performs QC testing for DuPont under contract.

The Quality Control unit utilizes an SAP computer quality control system for the specification, quality control data entry and product release. No product can be released for use without acceptance by the Quality Control unit, according to specified acceptance criteria.

Each bacteria fermentation product must meet specifications and must have a confirmation of identity through a PCR (polymerase chain reaction) test method based on strain specific primers for release of the product. Microbiological testing is performed by trained QC microbiologists in the Rochester plant laboratory and an approved external laboratory using standard methods.



Cleaning and quality testing of the process rooms and equipment are under the control of Manufacturing and Quality Assurance, following the established SOPs. Room access is controlled by appropriate signage, and additional protective gowning must be worn in processing rooms where product is potentially exposed. Operator sign-off for cleaning, sanitation and testing are required on proper documentation.

Process rooms are segregated from other manufacturing areas with appropriate closures. Room air quality is controlled via HEPA air filtration of incoming air and maintenance of positive pressure in the process rooms relative to adjacent processing areas. HEPA filtration operation is monitored for performance; air quality is monitored monthly by Quality Assurance.

Rooms and equipment used in manufacturing are approved for production only after cleaning, sanitization, and inspection. Prior to qualification of the process room for production, as specified in the appropriate SOP, the Spray Dried room is sprayed from ceiling to floor with 145–160°F water. All clean, out of place equipment having any product contact surfaces is thoroughly scrubbed / foamed with a neutral detergent cleaner, rinsed with cold water, and sanitized with an acid-based sanitizer. The floor is sanitized with acid-based sanitizer.

Batch records are maintained as per Standard Operating Procedures and are provided to Quality Assurance for each lot produced. Quality Assurance is responsible for batch ticket review. The flowchart of the manufacturing process is shown in Figure 1.




Figure 1. Manufacturing Flowchart

2.3 Specifications

The specifications for the food-grade product Bss-19, along with the specification methods, which have been validated for their stated purpose, are listed in Table 2 below.

Table 2. Bss-19 Specifications

Tested Parameters	Specification	Method
Viable cell count (CFU/g)	$\geq 2.25 \times 10^{11}$	In-house method
Color ¹	White to cream	Visual Inspection
Form ¹	Freeze-dried powder	Visual Inspection



Heavy Metals²		
Arsenic (ppm)	< 1.0 ppm	AOAC 984.27
Cadmium (ppm)	< 0.2 ppm	AOAC 984.27
Mercury (ppm)	< 0.05 ppm	EPA 7471
Lead (ppm)	< 0.5 ppm	AOAC 984.27
Microbiological Tests		
Coliform (CFU/g)	< 10	AOAC 991.14
<i>Escherichia coli</i> (CFU/g)	< 10	AOAC 991.14
<i>Salmonella</i>	Negative in 50 g	AOAC RI-121501
<i>Listeria</i>	Negative in 25 g	FDA BAM Chapter 10
<i>Staphylococcus coag⁺</i> (CFU/g)	< 10	FDA BAM Chapter 12
<i>B. cereus</i> (CFU/g)	< 10	AOAC 980.31
Molds and Yeast ³	< 100 CFU/g	USP 41-NF 36

Abbreviations: CFU, colony forming unit; AOAC, Association of Official Analytical Chemists; EPA, Environmental Protection Agency; FDA BAM, Food and Drug Administration's Bacteriological Analytical Manual; ppm, parts per million

¹ Internal Specification, not reported on CoA

² Based on annual surveillance testing, not generally reported on CoA

³ Tested on bulk intermediate powder, not generally reported on CoA

2.3.1 Batch Analysis

Production conformity and consistency of DuPont's Bss-19 are tested in production lots. Batch analyses of three non-consecutive lots are shown below and are reasonably consistent and met the product specifications for marker compounds, microbial analyses, and heavy metals (see Table 3).

Table 3. Bss-19 Batch Analyses

Tested Parameters	Specification	Lot No./Date of Manufacture		
		1493413902 03/29/2019	1493441559 04/11/2019	1493438028 04/19/2019
Viable cell count (CFU/g)	$\geq 2.25 \times 10^{11}$	4.03×10^{11}	3.63×10^{11}	3.73×10^{11}
Microbiological Tests				
Coliforms (CFU/g)	< 10	< 10	< 10	< 10
<i>Escherichia coli</i> (CFU/g)	< 10	< 10	< 10	< 10
<i>Salmonella</i> spp.	ND in 50 g	Negative/50 g	Negative/50 g	Negative/50g
<i>Listeria</i> spp.	ND in 25 g	Negative/25 g	Negative/25g	Negative/25g
<i>Staphylococcus aureus</i> (CFU/g)	< 10	< 10	< 10	< 10
<i>B. cereus</i> (CFU/g)	< 10	< 10	< 10	< 10
Heavy Metals				
Arsenic (ppm)	< 1.0	0.05	0.05	0.06
Cadmium (ppm)	< 0.2	0.03	0.02	0.02
Mercury (ppm)	< 0.05	< 0.02	< 0.02	< 0.02
Lead (ppm)	< 0.5	< 0.010	< 0.010	< 0.010

Abbreviations: CFU, colony forming units; ND, not detected; ppm, parts per million



2.3.2 Residual Pesticide Analysis

In accordance with standard operating procedures, DuPont is committed to annual surveillance testing of Bss-19 for pesticide residues. All lots in Table 3 of Bss-19 were analyzed using AOAC 2007.01 for the presence of hundreds of residual pesticides by an independent laboratory. All lots were free of all pesticides tested and complied with the product specifications.

2.3.3 Shelf–Life Stability

A long-term stability study for Bss-19 is currently underway.

2.4 Antibiotic Resistance

Resistance to therapeutic antibiotics in microbial pathogens is currently considered one of the greatest challenges in medicine and public health, as some infectious diseases may become virtually untreatable if they become non-respondent to their current therapies. Antibiotic resistance may be classified into two types;

- intrinsic/natural (when resistance is inherent to a bacterial species, and is a trait generally shared by all members of that species), and
- extrinsic/acquired (when a strain of a typically susceptible species is resistant to a given antimicrobial drug).

Extrinsic/acquired resistance can occur either from the gain of exogenous DNA or mutation of indigenous genes.^{5, 6} The gain of exogenous DNA occurs through horizontal gene transfer (HGT) via transformation, transduction or conjugation and many of the antibiotic resistance genes are carried on mobility elements such as plasmids, transposons, or phages.^{7,8} While intrinsic resistance likely presents a very low risk of dissemination, extrinsic/acquired resistance, especially when the relevant genes are associated with mobile genetic elements, can be transferred to pathogens or other commensal bacteria.^{7, 9}

It is generally recommended that resistance to antibiotics be assessed in all probiotic strains prior to marketing.^{5, 10-13} Antibiotic resistance is a complex phenomenon, in which microbial genetics and environmental stimuli both play an important role. Assessing resistance both phenotypically and genotypically is generally recommended. As detailed below, antibiotic susceptibility of Bss-19 was evaluated using both approaches.

Phenotypic evaluation of antibiotic resistance involves testing the capacity of a microorganism to survive in a medium containing different concentrations of antibiotics. Whereas most microorganisms can survive at low concentrations of many antibiotics, resistance is defined as the capacity to grow at antibiotic concentrations similar to those reached in the human body during therapeutic intervention.

Following EFSA recommendations and guidelines, DuPont assessed the phenotypic susceptibility of Bss-19 to the antibiotics detailed in the guidelines for *Bacillus* species, namely gentamycin, kanamycin, erythromycin, clindamycin, tetracycline, streptomycin, vancomycin, and chloramphenicol.¹⁴ One additional antibiotic, Ampicillin, was also tested although it is not a requirement per the EFSA guidelines for *Bacillus* species. The EFSA guidelines define a bacterial strain as sensitive or susceptible to an antibiotic when it is inhibited at a concentration of a specific antimicrobial equal or lower than the established cut-off value for that particular compound.

The assays on Bss-19 were performed using the ISO 10932 IDF223 method and VetMIC Lact-1 and 2 micro-dilution plates that include all antibiotics recommended by EFSA. All MIC values were below or equal to the microbial break points defined for *Bacillus* species except for chloramphenicol. Results are shown in Table 4 and indicate that Bss-19 is phenotypically sensitive to all antibiotics included in EFSA's guidelines for the *B. subtilis* species except for chloramphenicol.

Table 4. Bss-19 Phenotypic Resistance to Antibiotics Results

Antibiotic	MIC (mg/L)		Assessment
	Bss-19 (observed)	<i>B. subtilis</i> Breakpoints ⁵	
Ampicillin	0.06	n.r.	Sensitive
Clindamycin	2	4	Sensitive
Chloramphenicol	16	8	Resistant
Erythromycin	0.5	4	Sensitive
Streptomycin	4	8	Sensitive
Gentamycin	1	4	Sensitive
Kanamycin	4	8	Sensitive
Tetracycline	0.25	8	Sensitive
Vancomycin	1	4	Sensitive

MIC = Minimum Inhibitory Concentration; n.r. = not required (according to EFSA guidelines for *B. subtilis*)¹⁴

Genotypic evaluation of antibiotic resistance is a procedure in which the whole bacterial genome (chromosome and peripheral genetic elements, if any) is screened for putative genes of antibiotic resistance, as described in genetic databases. It is therefore a complementary procedure to the phenotypic assessment, in which the main objective is to discard the potential of transferring putative genes of antibiotic resistance to other microbes.

Comparison of all annotated Bss-19 protein sequences to the Comprehensive Antibiotic Resistance Database (CARD)¹⁵ revealed a putative homolog to a chloramphenicol acetyltransferase resistance protein (53% identity over 100% of query length). This gene was also found in both the *B. subtilis* inaquosorum DE111 and *B. subtilis* inaquosorum KCTC13429 genomes. Three types of HGT were



evaluated by DuPont and included: conjugative plasmids, transposases, and prophage/bacteriophage elements. A search of the Bss-19 draft genome sequence versus the ISFINDER database¹⁶ of known mobility element sequences revealed no mobility loci within 15 kb of the putative chloramphenicol resistance gene. Additionally, no intact or potentially active phage or prophage genomes were identified in the assembled Bss-19 genome sequence.

The lack of the presence of known mobility elements near the chloramphenicol resistance gene combined with the absence of active phage or prophage genomes suggests that acquired antibiotic resistance for the strain is not a concern. Additionally, while the observed MIC for Bss-19 was just above the cut-off value established by EFSA, one two-fold dilution above the EFSA cut-off value is still generally considered acceptable. This is because of the technical variation of the phenotypic method applied to determine antibiotic susceptibility. There is a certain amount of technical variability in all phenotypic antibiotic-resistance testing. Guidelines for this testing allow for this normal (technical) variation around the mean. The phenotypic test performed is generally based on two-fold broth dilutions. There is precedent for accepting levels that exceed the MIC cut-off by a single two-fold dilution due to normal variation around the mean; for example EFSA's "Scientific Opinion on the safety and efficacy of Oralin[®] (*Enterococcus faecium*) as a feed additive for calves for rearing, piglets, chickens for fattening, turkeys for fattening and dogs",¹⁷ in which the Oralin[®]'s MIC value exceeded the MIC cut-off for kanamycin by a single two-fold dilution, was considered to be within normal variation and did not raise concerns for safety by EFSA.

2.5 Genomic Analysis for Virulence and Pathogenicity

The genome of Bss-19 was screened using the Database of Bacterial ExoToxins for Human Health (DBETH)¹⁸ which revealed a single hit (70% identity over 90% of query length) to a hemolysin protein (HLY3_BACCE). However, the Bss-19 gene encoding this protein is highly conserved across the genus including many strains known to not be pathogens. Additionally, as discussed in Part 2.7, Bss-19 showed no hemolysis when analyzed in vitro.

A comparison of all Bss-19 protein sequences to the virulence factor database (VFDB)¹⁹ revealed no significant matches, indicating that Bss-19 does not contain any detected virulence factors.

2.6 Resistance to Gastric Acidity and Bile Salts

In many cases, probiotic microorganisms should be viable upon reaching the gastrointestinal tract. Some important traits that are believed to be relevant for surviving the passage through the gastrointestinal tract are tolerance to the acidic environment of the stomach and tolerance to the concentration of bile salts found in the small intestine. The extremely acidic environment of the stomach (pH of



approximately 2.0–3.0) kills the majority of potentially pathogenic bacteria, preventing infection.

For assessment of Bss-19, a modified gastric juice was utilized to simulate contact with a moderately acidic stomach fluid environment. Bile tolerance was estimated by determining the % recovery on bile containing agar medium compared to a non-bile containing control medium.

Culture was obtained from seed vials, inoculated into strain specific medium, and grown overnight. An aliquot of the overnight broth culture was pelleted, washed, and resuspended. An aliquot of the resuspended pellet was mixed with tempered gastric juice (hydrochloric acid and pepsin (0.32%) and pH 3.5). An aliquot was immediately diluted and plated in TSA agar with and without 0.3% ox-gall bile salt for a T0 control and a bile test result. The balance of sample in gastric juice was incubated for one hour at which time the final aliquot was taken for T1 plating using the same TSA media. Plates were allowed to solidify and incubated at 32°C under aerobic conditions for 48 hours. The results are shown in Table 5.

Table 5. Acid Tolerance and Bile Tolerance of Bss-19 in its Vegetative State and Spore Form

	Internal Identification	Acid tolerance		Bile tolerance		Date Tested
		<*	0%	<*	0%	
Vegetative state	DGCC12972*	<*	0%	<*	0%	5/13/2019
Spore form	DGCC12972*	****	100%	***	88.4%	5/30/2019

*DGCC12972 (DuPont Global Culture Collection) is used as the Internal Identification for Bss-19

Acid Tolerance rating

- **** Excellent (>90% survival in hydrochloric acid and pepsin, 0.32% (wt/v) at pH 3.5)
- *** Very Good (80–90% survival)
- ** Good (70–79% survival)
- * Fair (<69% survival)

Bile Tolerance Rating

- **** Excellent (>90% survival in 0.3% bile salt containing medium)
- *** Very Good (80–89% survival)
- ** Good (70–79% survival)
- * Fair (<69% survival)

Bss-19 in the vegetative state exhibited 0% survival following exposure to a low pH solution and 0% survival in bile salt solutions. Bss-19 in its spore form exhibits >90% survival in a low pH solution and >80% survival in a bile salt solution. These results suggest the spore form is necessary for survival through the gastrointestinal tract.

2.7 Hemolysis

Cultures of the strain were grown overnight in strain specific medium and temperature. An aliquot of the overnight culture was streaked onto prepared blood



agar plates and incubated at a strain specific temperature for 18 and 24 hours. Results showed that Bss-19 did not promote hemolysis when cultured on Sheep's blood agar plates.

As discussed in Part 2.2, genomic analysis of Bss-19 revealed a single hit to a hemolysin protein (HLY3_BACCE). However, the Bss-19 gene encoding this protein is highly conserved across the genus including many strains that do not show pathogenic activity. This is supported by the absence of hemolysis observed when the strain is grown on blood agar.

2.8 Biogenic Amine Formation

Some species and/or strains of lactic acid bacteria are able to produce biogenic amines (organic, basic, nitrogenous compounds formed mainly by the decarboxylation of amino acids), likely for use as metabolic energy and/or to increase acid resistance.²⁰ These amines are present in a wide range of foods (e.g., fermented food products), and although they are involved in many natural physiological processes, consuming large quantities of these amines can have undesirable consequences in some individuals. For example, if they are not properly biotransformed in the body, they can cause release of adrenaline/noradrenaline, cause gastric acid secretion, increased cardiac output, heart rate, and blood pressure, migraines, and increased blood sugar.²⁰ Biogenic amine formation in fermented foods has been reviewed by EFSA (2011)²¹ and Spano (2010).²⁰ Histamine and tyramine are considered the most concerning with regard to food safety.²¹

Generally, detection of strains possessing amino acid decarboxylase deaminase activity is helpful to aid in mitigating the accumulation of these amines in food products. Per assessment, Bss-19 did not contain histidine decarboxylase-encoding genes or tyrosine decarboxylase-encoding genes in its genome. Hence, it is unlikely that this strain can produce histamine or tyramine.

2.9 D(-)/L(+)-Lactic Acid Production

Bss-19 produces lactic acid (lactate) from the fermentation of carbohydrates. Lactate exists in two forms, a dextrorotary enantiomer (D-lactate) and a levorotary enantiomer (L-lactate). In humans, over 99% of lactate found in the blood is L-lactate. Testing D-lactate production by food microorganisms has been historically recommended likely because until relatively recently, it was believed that humans had a poor capacity for metabolizing D-lactate.¹¹ Some lactic acid bacteria as well as several other members of the intestinal microflora produce a mixture of L- and D-lactate.²² More recent studies have shown that much of the human gut microbiota produces D-lactate with no evidence of D-lactic acidosis, and in fact, humans are able to metabolize this isoform.²³⁻²⁹ D-lactate accumulation may only occur in cases

of impaired D-lactate metabolism and/or in subjects with a disturbed gastrointestinal function following bowel resection or Short Bowel Syndrome (SBS).^{25, 29-32}

Cultures of the strain were grown overnight in strain specific medium and temperature. An aliquot of overnight broth culture was pelletized, and the supernatant was retained. The supernatant was inactivated at 80°C for 15 minutes and diluted to achieve the desired total lactic acid concentration range. D(-)/L(+)-lactic acid detection was performed using a calorimetric measurement of lactate dehydrogenase activity for the respective isomers. Total lactic acid and isomer specific measurements were determined relative to control samples. Bss-19 produced an average of 100% of the L(+)-lactic acid isomer and 0% of the D(-)-lactic acid isomer.

2.10 Carbohydrate Analysis

Bss-19 capability to use and ferment different sugars as carbon sources was assessed following the API 50 CH system (Biomeréux, France). Results are shown in Table 6.

Table 6. Sugar Fermentation Capacity (API 50 CH) of Bss-19

Substrate	Growth	Substrate	Growth	Substrate	Growth
Control	-	Inositol	+	Melezitose	-
Glycerol	+	Mannitol	+	Raffinose	+
Erythritol	-	Sorbitol	+	Starch	+
D-Arabinose	-	a-methyl-D-Mannoside	-	Glycogen	+
L-Arabinose	+	a-methyl-D-Glucoside	-	Xylitol	-
D-Ribose	+	N-Acetylglucosamine	-	Gentiobiose	-
D-Xylose	-	Amygdaline	+	D-Turanose	+
L-Xylose	-	Arbutine	+	D-Lyxose	-
Adonidol	-	Esculin	+	D-Tagatose	-
Beta Methyl-D-Xyloside	-	Alicin	+	D-Fucose	-
Galactose	-	Celiobiose	+	L-Fucose	-
Glucose	+	Maltose	+	D-Arabitol	-
Fructose	+	Lactose	-	L-Arabitol	-
Mannose	+	Melibiose	+	Gluconate	-
Sorbose	-	Sucrose	+	2-Keto-gluconate	-
Rhamnose	+	Trehalose	+	5-Keto-gluconate	-
Dulcitol	-	Inulin	+		



2.11 Physical or Technical Effect

Bss-19 is not intended to produce any physical or other technical effects that are relevant to the safety of the ingredient.



Part 3: Intended Use and Dietary Exposure

For the purpose of this GRAS notice, Dupont's Bss-19 manufactured in accordance with current GMP, is intended to be used as an ingredient added to foods where standards of identity do not preclude such use. For example, it may be used in yogurt and other dairy products, soy products, beverages, chewing gum, confectionary, snacks, and other foods. It is not intended to be added to infant formula, or any products that would require additional regulatory review by USDA. The intended addition level to foods is up to 1×10^{10} CFU per serving (which is similar to levels of lactic acid bacteria found in traditionally fermented food products).³³

The addition of Bss-19 to some foods may be substitutive with regard to other GRAS *B. subtilis* strains' intended uses (e.g. GRN 831 and 905), or with regard to traditional uses of *B. subtilis*. However, uses in other foods may be considered more novel and additive with regard to exposure. Several older publications were located that looked at dietary patterns of Americans by analyzing the number of servings of foods consumed in a day. A publication from the USDA's Center for Nutrition Policy and Promotion (October 2000) states that men aged 51 and older consume the largest number of servings of food per day, at 18.2 servings/day.³⁴ Comparatively, women aged 19–24 consumed the least, at 12.5 servings/day. This data came from detailed 14-day food diaries from 5,752 adults in the 1992–1994 time period. Millen *et al.* (2005) used 24-hour dietary recall and diet history questionnaire data from the Eating at America's Table study (1997–1998) to analyze the mean number of servings per day consumed of food guide pyramid food groups by adults.³⁵ There were 497 women and 436 men that completed the study. The results (from the study's Table 1) suggest that the mean intake for men was approximately 27.8 servings per day and for women was 19.5 servings per day.

Using a most conservative estimation of consumption, if 100% of food servings contained Bss-19 at the maximum concentration of 1×10^{10} CFU per serving, highest consumers (men) would be exposed to approximately $1.82\text{--}2.78 \times 10^{11}$ CFU/day. Using 70 kg as a standard body weight, this is equivalent to $2.6\text{--}4.0 \times 10^9$ CFU/kg bw/day). This estimation is considered extremely conservative, as realistically, most foods will not contain Bss-19 due to the standards of identity of many foods, the fact that it will not be added to foods requiring additional USDA regulatory review, market share limitations, limited food matrix viability, and the fact that the ingredient will likely be "invisible" to many consumers, who may realize they are consuming a fermented food but likely will not be aware of the specific strain that they are consuming, reducing the likelihood that only food products containing this strain will be chosen and consumed. If a more realistic (but still highly conservative) estimate is used that 50% of food servings will contain the maximum intended use level of Bss-19, highest consumers (men) would be exposed to approximately 9.1×10^{10} to 1.4×10^{11} CFU/day (using 70 kg as a standard body weight, this is equivalent to $1.3\text{--}2.0 \times 10^9$ CFU/kg bw/day).



Part 4: Self-limiting Levels of Use

There are no known inherent self-limiting levels of use.



Part 5: Experience Based on Common Use in Food Prior to 1958

The GRAS conclusion for Bss-19 is based on scientific procedures, and thus, experience based on common use in food prior to 1958 is not considered pivotal information. Nevertheless, the historical use of foods fermented with *B. subtilis* is extensively discussed in Section 6.



Part 6: Narrative

6.1 History of Consumption

B. subtilis has a long history of human consumption, especially in fermented foods in Asia and Africa. Hong et al. (2005) describes at least nine probiotics on the market containing *B. subtilis* that are intended for human consumption, many of which have been on the market for decades without safety concerns.³⁶ Typical levels ranged from 1×10^6 to 1×10^9 CFU/serving.³⁶

B. subtilis is well known for its use in the traditional Japanese fermented soybean food called natto, which has a bacterial concentration reported as approximately 1×10^8 CFU/g.^{1, 36} Consumption of a 100g serving of natto containing this concentration of bacteria is equivalent to consumption of approximately 1×10^{10} CFU/serving. *B. subtilis* natto is recognized as FOSHU (Food For Specified Health Use) by the Japanese Ministry of Health, Labour, and Welfare.³⁷

B. subtilis is also listed in the inventory published by the International Dairy Federation (originally a collaboration with the European Food and Feed Culture's Association) documenting microbial species with technological beneficial roles in fermented food products, specifically as relates to use in soy (natto), emphasizing the species' long history of use.^{38, 39}

6.2 Regulatory Opinions

6.2.1 Europe

EFSA has developed an approach to safety assessments of microorganisms called Qualified Presumption of Safety (QPS). QPS generically assesses the safety of taxonomic groups or units (e.g. a bacterial species) independent of any particular pre-market authorization process. Any strain of microorganism, the identity of which can be unambiguously established and assigned to a QPS group, does not need to undergo further safety assessment by EFSA other than satisfying any qualifications specified in the QPS assessment. QPS is generally not based on a particular intended use unless stated in a specific qualification. Microorganisms not considered suitable for QPS remain subject to full safety assessments. The first QPS list was established in 2007.³ A full evaluation of the QPS list is undertaken every 3 years and results are published as Scientific Opinions (the next mandated Opinion was published in December 2019), while the list of microorganisms is maintained and re-evaluated approximately every 6 months to include new notifications to EFSA, and published as Panel Statements (the most recent Panel Statement was published in June of 2020 and includes research published through December 2019.⁴⁰ *B. subtilis* was granted QPS status in the first EFSA QPS publication in 2007, based on the substantial body of knowledge available on the species. However because some species within the *Bacillus* genus possess toxigenic traits, a QPS



qualification for this species is the absence of toxigenic activity.³ The other qualification is that the individual strains should not harbor any acquired antimicrobial resistance genes to clinically relevant antimicrobials. *B. subtilis* remains on the most recent EFSA QPS lists.^{40, 41}

6.2.2 United States

6.2.2.1 FDA GRAS

In the US, companies can notify FDA of their conclusion of GRAS status for a particular bacterial species/strain or ingredient on an individual basis, and for specific intended uses. It was estimated in 2009 that approximately 40% of food enzymes marketed in Europe were produced by bacterial/fungal recombinant strains, and vitamins, amino acids, and polysaccharides are also obtained from recombinant strains.⁴² Fifteen GRAS notices related to *B. subtilis* strains (mainly as recombinant strains utilized to isolate enzymes) are listed in FDA’s GRN inventory. Of these, 14 have received the no questions letter from FDA, one was ceased to be evaluated at the notifier’s request (this was actually a notice for *B. subtilis* itself, and the reason for requesting that FDA cease to evaluate is unknown). A brief summary of these notifications is shown in Table 7.

Table 7. FDA GRAS Notifications that Include *B. subtilis* Strains

FDA GRN Number	Strain Description	Date of Closure	Comments
20	Pullulanase derived from <i>B. subtilis</i> carrying a gene encoding pullulanase from <i>B. naganoensis</i>	September 1999	FDA had no questions.
114	Pectate lyase enzyme preparation from <i>B. subtilis</i>	January 2003	FDA had no questions.
205	Pullulanase enzyme preparation from <i>B. subtilis</i> expressing the pullulanase gene from <i>B. acidopullulyticus</i>	December 2006	FDA had no questions.
274	Branching glycosyltransferase enzyme preparation from <i>B. subtilis</i> expressing a branching glycosyltransferase gene from <i>Rhodothermus obamensis</i>	June 2009	FDA had no questions.
406	1,4- α -glucan branching enzyme preparation from <i>B. subtilis</i> strain 168 expressing the glucan branching enzyme gene from <i>Aquifex aeolicus</i> strain VF	September 2012	FDA had no questions.
476	Asparaginase enzyme preparation produced by genetically modified <i>B. subtilis</i>	February 2014	FDA had no questions.
562	<i>B. subtilis</i>	April 2015	At the notifier’s request, FDA ceased to evaluate the notice.



579	Lactase from <i>Bifidobacterium bifidum</i> produced in <i>B. subtilis</i>	November 2015	FDA had no questions.
592	β -glucanase from <i>B. subtilis</i>	October 2015	FDA had no questions.
649	β -galactosidase enzyme preparation from <i>B. circulans</i> produced in <i>B. subtilis</i>	November 2016	FDA had no questions.
714	Subtilisin from <i>B. amyloliquefaciens</i> produced in <i>B. subtilis</i>	February 2018	FDA had no questions.
746	Maltogenic amylase from <i>Geobacillus stearothermophilus</i> produced in <i>B. subtilis</i>	June 2018	FDA had no questions.
751	Maltogenic alpha-amylase from <i>B. stearothermophilus</i> produced in <i>B. subtilis</i>	July 2018	FDA had no question
831	<i>B. subtilis</i> DE111	October 2019	FDA had no questions.
905	<i>B. subtilis</i> DSM 32444	June 2020	FDA had no questions.

6.2.2.2 Code of Federal Regulations

There are three regulations in the 21 CFR for enzyme preparations allowed in foods, derived from nonpathogenic/nontoxicogenic *B. subtilis* strains, as follows:

- 21 CFR 173.115 Alpha-acetolactate decarboxylase enzyme from recombinant *B. subtilis*;
- 21 CFR 184.1148 Carbohydrase enzyme from *B. subtilis*;
- 21 CFR 184.1150 Protease enzyme from *B. subtilis*.

Of note, a number of *B. subtilis* strains are registered with the Environmental Protection Agency (EPA) as microbial pesticides for various uses.⁴³ EPA describes *B. subtilis* as “a ubiquitous bacteria commonly found in various ecological niches including soil, water, and air which does not have a history of pathogenicity from contact in the environment”.⁴³

6.2.3 Canada

A number of products containing *B. subtilis* are approved to be marketed under the Natural Health Products Regulations of Health Canada, including products containing *B. subtilis* strain DE111 (NPNs 80077102 & 80080178) and *B. subtilis* strain R0179 (NPNs 80045131, 80051112, 80054028, etc.).

6.3 Safety Information

Toxicological studies have been published on various strains of *B. subtilis* and are summarized in subpart 6.3.1. Additionally, human studies on the strain of closest similarity, *B. subtilis* DE111 and other *B. subtilis* strains are discussed in subpart 6.3.3. While no published human or toxicological studies were located for *B. subtilis*



Bss-19 specifically, an unpublished acute oral toxicity study was performed on the strain and is summarized in subpart 6.3.2. The studies reviewed do not suggest any concerns related to the safety of the strain.

6.3.1 Toxicological Studies on *B. subtilis* strains

Zhang et al. (2013) studied *B. subtilis* strain Tpb55 in an acute gavage toxicity study and a maximum tolerable dose study in mice and rats, respectively, in which animals were observed for 14 days after treatment.⁴⁴ The LD₅₀ was determined to be greater than 5000 mg/kg in both the mice and rats, as no deaths occurred and in addition no “symptoms of poisoning”, or abnormal anatomic structures were observed. Similarly, no increase in the incidence of micronuclei or chromosomal aberrations occurred in in vivo mouse assays up to the highest dose tested (2500 mg/kg bw/day for two days or five days in a bone marrow polychromatic erythrocyte micronucleus study and a primary spermatocyte chromosomal aberration study, respectively). The spore content was 3×10^{10} CFU/g (7.5×10^{10} CFU/kg bw/day) in all of the studies.

Two toxicity studies published in Korean and Chinese, respectively, were identified and the translated abstracts are described below. Both studies were also described in GRN 831 on *B. subtilis* DE111, which received the FDA no questions letter. Kyoung-Hoon et al. (2015) administered a single oral dose of *B. subtilis* JNS to mice at 2000 mg/kg bw followed by observation for 14 days.⁴⁵ The authors reported that no significant change in general conditions, mortalities, body weight changes, clinical signs, autopsy findings, or presence of gross lesions were observed. Nakamura et al. (1999) performed a 90-day subchronic toxicity study in both sexes of F344 rats by feeding of CRF-1 pellet diet containing 0%, 0.18%, 0.55%, 1.66% and 5% *B. subtilis* gum (strain and CFUs of *B. subtilis* were not specified).⁴⁶ Five groups consisted of 10 males and 10 females each whereby rats were randomly allocated. No animals died during the administration period and there were no differences in body weights or food intakes among groups of either sex. Kidney weight was significantly increased in both sexes in groups given concentrations of 1.66% or more *B. subtilis*, but these increases were slight and serum biochemistry and histopathology did not show any toxicological effects. The authors concluded that these findings indicated that the treatment of *B. subtilis* gum in the diet for 90 days does not exert toxicity in rats even at the highest dose tested.

Sorokulova et al. (2008) described a number of studies on *B. subtilis* VKPM B2335 (BS3).⁴⁷ Groups of 10 BALB/c male mice were each administered the test article at doses of 5×10^7 , 5×10^8 , and 5×10^9 CFU/mouse both intravenously and intraperitoneally, and orally at doses of 5×10^7 , 5×10^8 , and 2×10^{11} CFU/mouse (control group mice were given sterile PBS). Animals were observed for seven days, and on days two and seven, five animals from each group were euthanized and internal organs were observed macroscopically. For the groups treated orally, tissues were collected for histopathological examination (liver, kidneys, lungs, spleen, intestine, mesenteric lymph nodes, brain, thymus, and tissues around the throat). There were no treatment related deaths, even in groups given the strain



intravenously. There were no adverse effects (AEs) observed related to activity and weight. All animals were reported to be clinically healthy. There were no differences in visceral organ appearance or histopathological examinations between treated and control groups. The authors also described a 10-day repeated dose study using oral administration in groups of ten mice (1×10^6 CFU/day), rabbits (1×10^9 CFU/day), and piglets (1×10^9 CFU/day), as well as a 30-day repeated dose study using groups of ten rabbits. There were no AEs noted or changes in hematology values, or gross or histopathological findings compared to controls.

Hong et al. (2008) performed a repeated-dose gavage study of *B. subtilis* natto in 6 male New Zealand White rabbits as compared to an equal number of controls.⁴⁸ A dose of 1×10^9 spores was given to the treated animals daily for 30 days. Blood samples were taken on the last day and the liver, kidneys, spleen, small intestines, and mesenteric lymph nodes were collected for histopathological examination. There were no AEs in health status or feed intake, and no changes in hematology or visceral organs or tissues were observed as compared to controls. The authors additionally studied a single dose (1×10^{12} CFU) of *B. subtilis* natto in guinea pigs, as briefly described in the same publication. There were no findings related to appetite, behavior, feces, weight gain, or histopathology 17 days after administration in feed.

Tompkins et al. (2008) performed a 28-day repeated dose study in three groups of ten Sprague-Dawley albino rats using 2×10^9 CFU/kg bw/day *B. subtilis* R0179 or *E. faecium* R0026 or control administered by gavage.⁴⁹ Animals were monitored daily for potential signs of toxicity and groups were compared for mortality, morbidity, behavior, body mass, food consumption, gross pathology, intestinal colonization, and infection. Any changes in skin, fur, eyes, mucous membranes, secretions/excretion, autonomic activity, gait, posture, handling response, sensory reactivity, and movement were noted. At the end of treatment, the liver, kidneys, spleen, heart, and lungs were subjected to histopathology and microbiological exams. No findings, other than a lower heart mass (10%) in female rats, were noted. The heart to body weight ratio was not affected by the treatment in these animals, and no histopathological findings were mentioned. The *B. subtilis* strain was not observed microbiologically except in the intestinal content of treated animals.

Additionally, Cell-Free Supernatants (CFSS) of *B. subtilis* KATMIRA were evaluated by a bacterial reverse mutation assay (Ames Salmonella assay) and showed no mutagenicity.⁵⁰

6.3.2. Unpublished Acute Toxicity Study on *B. subtilis* Bss-19

An initial limit dose of 5000 mg/kg *B. subtilis* Bss-19 was administered to one healthy female Sprague-Dawley rat by oral gavage. Due to the absence of mortality in this animal, two additional female rats received the same dose. All animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days after dosing. Body weights were recorded prior to administration



and again on days 7 and 14. Necropsies were performed on all animals at terminal sacrifice. All animals survived test substance administration, gained body weight, and appeared active and healthy during the study. There were no signs of gross toxicity, AEs or abnormal behavior. No gross abnormalities were noted upon necropsy. The LD₅₀ was determined to be greater than 5000 mg/kg bw in female rats.

6.3.3. Human Studies

The safety of Bss-19 has not been formally investigated in healthy adult subjects. However, many recent human clinical studies have been and continue to be published on the strain of closest similarity, *B. subtilis* DE111 and on other *B. subtilis* strains.⁵¹⁻⁵⁴ Due to the large amount of published human studies, included below are clinical studies located in the literature published since EFSA's most recent Opinion in 2016, which addressed studies published up to June 2016.

6.3.3.1. *B. subtilis* DE111

In a human clinical trial investigating the safety of *B. subtilis* DE111, Maher (2019) gave 5×10^9 CFU *B. subtilis* DE111 in a single capsule or placebo daily to 41 healthy young adults for an average of 20 days.⁵⁵ Blood samples (comprehensive metabolic panel, lipid panel, C-reactive protein (CRP)) and stool samples were collected at the beginning and end of the study. Serum glucose levels were significantly lower in the treatment group when comparing pre to post capsule consumption. Triglycerides remained the same within the treatment group, while the control group displayed a significant increase from pre to post capsule consumption. There was no significant variation from the normal range of CRP. The authors discussed that the decrease in serum glucose had been observed in two animal studies where, in the first study, a compound isolated from *B. subtilis* (1-Deoxynojirimycin) helped to improve diabetic conditions in bovine calves and, in a second study, freeze-dried cultures of a combination of bacteria reduced blood glucose levels in rats with elevated glucose levels. The authors concluded that daily ingestion of one capsule containing approximately 5×10^9 CFU *B. subtilis* was well tolerated in healthy young adults.

Cuentas et al. (2017) investigated the use of 1×10^9 CFU *B. subtilis* DE111 or placebo daily for 105 days in 50 adults. Comprehensive metabolic panels, lipid panels, and CRP levels stayed within normal reference ranges for the treatment and placebo groups with no significant serum level differences. Additionally, no AEs were reported.⁵⁶

In addition to the safety study and clinical study above, the following two clinical studies were conducted which did not have any reported AEs. Toohey et al. (2018) investigated the effects of 5×10^9 CFU *B. subtilis* DE111 or placebo daily on 23 Division I female athletes for 10 weeks—no AEs were reported.⁵⁷ Townsend et al. (2018) gave 1×10^9 CFU *B. subtilis* DE111 or placebo daily to 25 Division I male athletes for 12 weeks—no AEs were reported.⁵⁸



6.3.3.2. Other *B. Subtilis* Strains

Penet et al. (2019) gave 5×10^9 CFUs of *B. subtilis* MB40 or placebo daily to 100 subjects for four weeks.⁵⁹ There were no statistically significant differences between groups with regard to anthropometric, vital, hematological and clinical chemistry parameters. Reported AEs were similar between groups and consisted of constipation, diarrhea, flatulence, dry mouth, abdominal discomfort, increased appetite and paresthesia. All AEs were resolved before end-of-study. Soman and Swamy (2019) evaluated the safety in a combination of 2×10^9 CFUs of *B. coagulans*, *B. clausii*, and *B. subtilis* versus placebo in 60 subjects for 30 days.⁶⁰ No AEs were reported in any subject during the study period. Hatanaka et al. (2018) gave 2.2×10^9 *B. subtilis* C3102 spores or placebo daily to 88 healthy adults with loose stool for eight weeks and did not report any AEs.⁵¹ Lefevre et al. (2017) described that after 40 total days of treatment with *B. subtilis* CU1 (2×10^9 spores/day) compared to placebo in 100 elderly human subjects, no undesirable physiological effects or biological safety concerns with regard to AEs, liver and kidney function markers, complete blood counts, hemodynamic parameters, and vital signs were noted.^{52, 61} Alkaya et al. (2017) investigated the use of 5×10^7 CFU/day of combined *B. subtilis*, *B. megaterium*, and *B. pumilus* spores in subjects for eight weeks—no AEs occurred.⁵³

Further, one study published before the most recent EFSA Opinion, Hanifi et al. (2015), is included because it evaluated oral dose-response tolerance at similar or higher daily dosages than the intended use levels of Bss-19. To evaluate oral dose-response tolerance, Hanifi et al. (2015) gave 81 subjects *B. subtilis* R0179 at doses of 0.1×10^9 , 1×10^9 , and 10×10^9 CFU/day or placebo for 4 weeks. The test article was well tolerated at all doses and survived passage through the human GI tract.⁵⁴

6.3.4 Opportunistic Infections

Rare infections caused by *B. subtilis* have been described in the literature. For example, a 73 year old male with chronic lymphocytic leukemia had a positively identified recurrent septicemia caused by *B. subtilis*.⁶² Another case report in the literature involved a patient with an esophageal perforation who had bacteremia and mediastinitis due to co-infection with *B. subtilis* and *B. licheniformis*.⁶³ Overall, infections with *B. subtilis* occur at very low rates, and generally occur in hospital settings in immunocompromised patients and/or during medical procedures.⁶²⁻⁶⁴

6.4 Allergenicity

Bss-19 does not contain or have added any of the eight major allergens (milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans) identified, and required to be disclosed in labeling, in the Food Allergen Labeling and Consumer Protection Act (FALCPA). No reports of allergic reactions to *B. subtilis* were found in our investigations.



No reports of allergic reactions to *B. subtilis* were found in our investigations. Given total exposure together with results of toxicological and clinical studies, the allergic potential of *B. subtilis* can be considered very low.

6.5 Past Sales and Reported Adverse Events

Bss-19 has never been released on the market and therefore has no past sales or past reported AEs to account for. No FDA letters regarding concern for safety to companies that market products containing *B. subtilis* were located. A search of FDA's Recalls, Market Withdrawals, & Safety Alerts search engine and FDA's Center for Food

Safety and Applied Nutrition Adverse Event Reporting System did not uncover any mention of *B. subtilis* products. All databases were accessed on June 2, 2020.

6.6 Basis for the GRAS Conclusion

DuPont's Bss-19 has been the subject of a thorough safety assessment as described above. The totality of evidence supporting safety is comprised of data and information that establish the safety of Bss-19 under the conditions of its intended use and data and information that is corroborative of safety. The general availability and general acceptance, throughout the scientific community of qualified experts, of the data and information that establish the safety of Bss-19 under its intended conditions of use establish the general recognition of this data and information. Together, the establishment of safety based on scientific procedures and its general recognition form the basis for DuPont's conclusion of GRAS status of Bss-19 for its intended use.

6.6.1 Data and Information that Establish Safety

The scientific data, information, and methods forming the basis of this conclusion are:

- The establishment of identity via 16S rRNA sequence as well as complete genome sequencing, demonstrating unequivocally that it is a strain of the *B. subtilis* subspecies *inaquosorum* with established phenotypic characteristics;
- The analyses and resulting data showing Bss-19 lacks resistance to clinically relevant antibiotics per European Food Safety Authority (EFSA) minimal inhibitory concentration cut-offs and guidelines, with the exception of chloramphenicol, where further investigation by DuPont showed that the resistance is not expected to be transferrable;
- The lack of potential of Bss-19 to produce toxins or virulence factors that have been demonstrated to be virulent to hosts (via comparison of genomic sequences to known virulence sequences in the DBETH exotoxin protein database);



- The methods of manufacture, specifications, as well as batch analyses, showing that all specifications are met for each batch, demonstrating safe production methods and robust quality control standards for Bss-19;
- The intended use as an ingredient in foods at an addition level of up to 1×10^{10} CFU per serving, which is in line with addition levels for other GRAS microbial ingredients (including *B. subtilis* in GRN 831) as well as with levels of fermenting bacteria found naturally in various fermented foods, with an estimated exposure of 9.1×10^{10} – 1.4×10^{11} CFU/day (1.3 – 2.0×10^9 CFU/kg bw/day) by conservatively assuming consumption at the maximum intended use addition level in 50% of all food servings daily;
- A previous GRAS notice to FDA (GRN 831) for a very similar strain, *B. subtilis inaquosorum* strain DE111, received a no questions letter from FDA for use as an ingredient in cow's milk and soy-based non-exempt infant formula for term infants at a maximum level of 2×10^8 CFU/100 mL and in baked goods and baking mixes; beverages and beverage bases; breakfast cereals; chewing gum; coffee and tea; condiments and relishes; confections and frostings; dairy product analogs; fats and oils; fruit juices; frozen daily deserts and mixes; fruit and water ices; gelatins; puddings and fillings; grain products and pastas; soft/hard candy and cough drops; herbs, seeds, spices, seasonings, blends, extracts, and flavorings; jams and jellies; milk and milk products; nuts and nut products; plant protein products; processed fruits; processed vegetables and vegetable juices; snack foods; soups and soup mixes; sugar; and sweet sauces, toppings, and syrups at addition levels from 1×10^6 to 1×10^{10} CFU/serving. The estimated daily intake (EDI) for the strain was determined to be 1.3×10^{11} CFU/day which FDA did not object to.
- Another previous GRAS notice to FDA (GRN 905) for another *B. subtilis* strain, *B. subtilis* DSM 32444, received a no questions letter from FDA for use as in ingredient in beverages (milk drinks, protein high energy sports drinks, hot beverages, and juices) and dry and shelf-stable products (cereals, cookies, gums, and confectionary) at a maximum level of 1×10^9 CFU/serving. The EDI for the strain was determined to be 5.0×10^9 CFU/day which FDA did not object to.

6.6.2 Data and Information that are Corroborative of Safety

- *B. subtilis*' EFSA QPS status for food and feed use, at any reasonable dose/intended use, suggesting no further regulatory review prior to introduction of new strains into the European food supply, other than the qualifications that it must be verified to not possess toxigenic traits or harbor acquired antimicrobial resistance genes;
- The documented long history of safe human consumption of *B. subtilis* as a common bacterial species in fermented foods,³⁸ such as in natto (with



concentrations of approximately 1×10^8 CFU/gram, equivalent to approximately 1×10^{10} CFU/ 100 g serving), over decades without known concerns for safety;^{48, 49}

- The lack of serious adverse events reported in clinical trials using *B. subtilis* at daily dosages up to 1×10^{10} CFU/day;
- Agreement in the literature that it is highly unlikely that a microorganism maintained in pure culture, with a history of safe use, would become unsafe as a result of mutation (genetic drift), production changes, or delivery format changes;⁶⁵⁻⁶⁷
- An unpublished acute oral toxicity study showing the acute oral LD₅₀ of *B. subtilis* Bss-19 is greater than 5000 mg/kg bw in female rats.

6.6.3 General Recognition

The scientific data, information, and methods herein reported, that provide the basis of this GRAS conclusion by scientific procedures are published and available in the public domain. Part 7 of this GRAS notice contains the citations for the published studies. These publicly available data and information fulfill the requirement of the GRAS standard for general availability of the scientific data, information, and methods relied on to establish the safety of Bss-19 for its intended conditions of use. The peer-review of the published studies and lack of Letters to the Editor or other dissenting opinions provide ample evidence of general recognition among qualified experts that there is reasonable certainty that consumption of Bss-19 for its intended use is not harmful. The general availability and acceptance of these scientific data, information, and methods satisfy the criterion of the GRAS standard that general recognition of safety requires common knowledge throughout the scientific community knowledgeable about the safety of substances directly or indirectly added to food that there is reasonable certainty that the substance is not harmful under the conditions of its intended use.

6.6.4 Data and Information that are Inconsistent with the GRAS Conclusion

We have reviewed the available data and information and are not aware of any data and information that are, or may appear to be, inconsistent with our conclusion of GRAS status.

6.6.5 Information that is Exempt from Disclosure under FOIA

There are no data or information in this report that are considered trade secret or commercial or financial information that is privileged or confidential.



Part 7: Supporting Data and Information

Literature searches for the safety assessment described in Part 6 of this GRAS notice were conducted through July 2019 and again on June 2, 2020.

7.1 Data and Information that are *not* Generally Available

An unpublished acute oral toxicity study was provided by DuPont and is part of the basis of the determination of safety (subpart 6.3.2).

7.2 References that *are* Generally Available

1. Kunst F, Ogasawara N, et al. The complete genome sequence of the gram-positive bacterium *Bacillus subtilis*. *Nature*. 1997;390(6657):249-56
2. Permpoonpattana P, Hong HA, et al. Evaluation of *Bacillus subtilis* strains as probiotics and their potential as a food ingredient. *Benef Microbes*. 2012;3(2):127-35
3. EFSA. Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA. Opinion of the Scientific Committee. *The EFSA Journal*. 2007;587:1-16
4. Darling AC, Mau B, et al. Mauve: multiple alignment of conserved genomic sequence with rearrangements. *Genome Res*. 2004;14(7):1394-403
5. EFSA. Scientific Opinion. Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. *EFSA Journal*. 2012;10(6):2740
6. Ammor MS, Florez AB, et al. Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria. *Food Microbiol*. 2007;24(6):559-70
7. Balcazar JL. Bacteriophages as vehicles for antibiotic resistance genes in the environment. *PLoS Pathog*. 2014;10(7):e1004219
8. Bennett PM. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. *Br J Pharmacol*. 2008;153 Suppl 1:S347-57
9. Mathur S and Singh R. Antibiotic resistance in food lactic acid bacteria--a review. *Int J Food Microbiol*. 2005;105(3):281-95
10. WHO. The world is running out of antibiotics, WHO report confirms; 2017.
11. FAO/WHO. Guidelines for the evaluation of probiotics in food. 2002. 1-11.
12. EFSA Panel on Biological Hazards (BIOHAZ), Ricci A, et al. Scientific Opinion on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA. *EFSA Journal*. 2017;15(3):177
13. Bernardeau M, Vernoux JP, et al. Safety assessment of dairy microorganisms: the *Lactobacillus* genus. *Int J Food Microbiol*. 2008;126(3):278-85
14. EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP). Guidance on the characterisation of microorganisms used as feed additives or as production organisms. *EFSA Journal*. 2018;16(3):5206



15. Jia B, Raphenya AR, et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. *Nucleic Acids Res.* 2017;45(D1):D566-D573
16. Siguier P, Perochon J, et al. ISfinder: the reference centre for bacterial insertion sequences. *Nucleic Acids Res.* 2006;34(Database issue):D32-6
17. EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP). Scientific Opinion on the safety and efficacy of Oralin® (*Enterococcus faecium*) as a feed additive for calves for rearing, piglets, chickens for fattening, turkeys for fattening and dogs. *EFSA Journal.* 2014;12(6):3727
18. Chakraborty A, Ghosh S, et al. DBETH: a Database of Bacterial Exotoxins for Human. *Nucleic Acids Res.* 2012;40(Database issue):D615-20
19. Chen L, Yang J, et al. VFDB: a reference database for bacterial virulence factors. *Nucleic Acids Res.* 2005;33(Database issue):D325-8
20. Spano G, Russo P, et al. Biogenic amines in fermented foods. *Eur J Clin Nutr.* 2010;64 Suppl 3:S95-100
21. EFSA Panel on Biological Hazards (BIOHAZ). Scientific Opinion on risk based control of biogenic amine formation in fermented foods. *EFSA Journal.* 2011;9(109):2393
22. Stiles ME and Holzapfel WH. Lactic acid bacteria of foods and their current taxonomy. *Int J Food Microbiol.* 1997;36(1):1-29
23. Ewaschuk JB, Naylor JM, et al. D-lactate in human and ruminant metabolism. *J Nutr.* 2005;135(7):1619-25
24. Petersen C. D-lactic acidosis. *Nutr Clin Pract.* 2005;20(6):634-45
25. Connolly E, Abrahamsson T, et al. Safety of D(-)-lactic acid producing bacteria in the human infant. *J Pediatr Gastroenterol Nutr.* 2005;41(4):489-92
26. Haschke-Becher E, Brunser O, et al. Urinary D-lactate excretion in infants receiving *Lactobacillus johnsonii* with formula. *Ann Nutr Metab.* 2008;53(3-4):240-4
27. Haschke-Becher E, Baumgartner M, et al. Assay of D-lactate in urine of infants and children with reference values taking into account data below detection limit. *Clin Chim Acta.* 2000;298(1-2):99-109
28. Hove H and Mortensen PB. Colonic lactate metabolism and D-lactic acidosis. *Dig Dis Sci.* 1995;40(2):320-30
29. Uribarri J, Oh MS, et al. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. *Medicine (Baltimore).* 1998;77(2):73-82
30. Munakata S, Arakawa C, et al. A case of D-lactic acid encephalopathy associated with use of probiotics. *Brain Dev.* 2010;32(8):691-4
31. Ku W, Lau D, et al. Probiotics Provoked D-lactic Acidosis in Short Bowel Syndrome: Case Report and Literature Review. *HK J Paediatr.* 2006;11:246-254
32. de Vrese M, Koppenhoefer B, et al. D-lactic acid metabolism after an oral load of DL-lactate. *Clin Nutr.* 1990;9(1):23-8
33. Rezac S, Kok CR, et al. Fermented Foods as a Dietary Source of Live Organisms. *Front Microbiol.* 2018;9:1785
34. Basiotis P, Lino M, et al. Consumption of Food Group Servings: People's Perceptions vs. Reality. *Nutrition Insights.* 2000. 20: 1-2



35. Millen AE, Midthune D, et al. The National Cancer Institute diet history questionnaire: validation of pyramid food servings. *Am J Epidemiol.* 2006;163(3):279-88
36. Hong HA, Duc le H, et al. The use of bacterial spore formers as probiotics. *FEMS Microbiol Rev.* 2005;29(4):813-35
37. Shimizu T. Health claims on functional foods: the Japanese regulations and an international comparison. *Nutr Res Rev.* 2003;16(2):241-52
38. International Dairy Federation. Safety demonstration of microbial food cultures (MFC) in fermented food products. Bulletin of the International Dairy Federation 455/2012. 2012. 62.
39. International Dairy Federation. Inventory of microbial food cultures with safety demonstration in fermented food products. Update of the Bulletin of the IDF No. 455/2012: Safety demonstration of Microbial Food Cultures (MFC) in fermented food cultures. Bulletin of the International Dairy Federation 495/2018. 2018. 71.
40. EFSA Panel on Biological Hazards (BIOHAZ). Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019. *EFSA Journal.* 2019;17(7):5753
41. EFSA Panel on Biological Hazards (BIOHAZ). Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 5: suitability of taxonomic units notified to EFSA until September 2016. *EFSA Journal.* 2016;15(3)
42. Aguilera J, Gomes AR, et al. Principles for the risk assessment of genetically modified microorganisms and their food products in the European Union. *Int J Food Microbiol.* 2013;167(1):2-7
43. Biopesticides and Pollution Prevention Division, Office of Pesticide Programs, et al. Biopesticide Registration Action Document. *Bacillus subtilis* strain QST 713. 2006. 41.
44. Zhang C, Zhang Y, et al. Toxicological and safety evaluation of *Bacillus subtilis* strain Tpb55. *Advanced Materials Research.* 2013;807-809:1947-1953
45. Kim K-H, Jeong C, et al. Single dose oral toxicity of *Bacillus subtilis* JNS in ICR mice [Abstract only]. *J Korean Soc Food Sci Nutr.* 2015;44(1):24-28
46. Nakamura H, Imazawa T, et al. A 90-day subchronic oral toxicity study of *Bacillus subtilis* gum in F344 rats [In Japanese. English abstract only]. *Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku.* 1999(117):119-22
47. Sorokulova IB, Pinchuk IV, et al. The safety of two *Bacillus* probiotic strains for human use. *Dig Dis Sci.* 2008;53(4):954-63
48. Hong HA, Huang JM, et al. The safety of *Bacillus subtilis* and *Bacillus indicus* as food probiotics. *J Appl Microbiol.* 2008;105(2):510-20
49. Tompkins TA, Hagen KE, et al. Safety evaluation of two bacterial strains used in Asian probiotic products. *Can J Microbiol.* 2008;54(5):391-400
50. AlGburi A, Volski A, et al. Safety properties and probiotic potential of *Bacillus subtilis* KATMIRA1933 and *Bacillus amyloliquefaciens* B-1895. *Advances in Microbiology.* 2016;6(6):432-452
51. Hatanaka M, Yamamoto K, et al. Effect of *Bacillus subtilis* C-3102 on loose stools in healthy volunteers. *Benef Microbes.* 2018;9(3):357-365



52. Lefevre M, Racedo SM, et al. Safety assessment of *Bacillus subtilis* CU1 for use as a probiotic in humans. *Regul Toxicol Pharmacol.* 2017;83:54-65
53. Alkaya B, Laleman I, et al. Clinical effects of probiotics containing *Bacillus* species on gingivitis: a pilot randomized controlled trial. *J Periodontal Res.* 2017;52(3):497-504
54. Hanifi A, Culpepper T, et al. Evaluation of *Bacillus subtilis* R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. *Benef Microbes.* 2015;6(1):19-27
55. Maher M. Tolerance and effect of a probiotic supplement delivered in capsule form. *Food and Nutrition Sciences.* 2019;10(6):626-634
56. Cuentas A, Deaton J, et al. The effect of *Bacillus subtilis* DE111 on the daily bowel movement profile for people with occasional gastrointestinal irregularity. *J Prob Health.* 2017;5(4):10000189
57. Toohey JC, Townsend JR, et al. Effects of Probiotic (*Bacillus subtilis*) Supplementation During Offseason Resistance Training in Female Division I Athletes. *J Strength Cond Res.* 2018
58. Townsend JR, Bender D, et al. Effects of Probiotic (*Bacillus subtilis* DE111) Supplementation on Immune Function, Hormonal Status, and Physical Performance in Division I Baseball Players. *Sports (Basel).* 2018;6(3)
59. Penet C, Kramer R, et al. A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of *Bacillus subtilis* MB40 to Reduce Abdominal Discomfort, Gas, and Bloating. *Altern Ther Health Med.* 2019
60. Soman RJ and Swamy MV. A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain *Bacillus* probiotic blend for undiagnosed gastrointestinal discomfort. *Int J Colorectal Dis.* 2019;34(11):1971-1978
61. Lefevre M, Racedo SM, et al. Probiotic strain *Bacillus subtilis* CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. *Immun Ageing.* 2015;12:24
62. Oggioni MR, Pozzi G, et al. Recurrent septicemia in an immunocompromised patient due to probiotic strains of *Bacillus subtilis*. *J Clin Microbiol.* 1998;36(1):325-6
63. Jeon YL, Yang JJ, et al. Combined *Bacillus licheniformis* and *Bacillus subtilis* infection in a patient with oesophageal perforation. *J Med Microbiol.* 2012;61(Pt 12):1766-9
64. Matsumoto S, Suenaga H, et al. Management of suspected nosocomial infection: an audit of 19 hospitalized patients with septicemia caused by *Bacillus* species. *Jpn J Infect Dis.* 2000;53(5):196-202
65. Pariza MW, Gillies KO, et al. Determining the safety of microbial cultures for consumption by humans and animals. *Regul Toxicol Pharmacol.* 2015;73(1):164-71
66. Stevens H and Nabors L. Microbial food cultures: a regulatory update. *Food Tech.* 2009;63(3):36-41
67. Sanders ME, Klaenhammer TR, et al. Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. *Ann N Y Acad Sci.* 2014;1309:1-18

Viebrock, Lauren

From: Amy Clewell <amy@aibmr.com>
Sent: Friday, May 7, 2021 5:01 PM
To: Viebrock, Lauren
Cc: John Endres; Jared Brodin
Subject: [EXTERNAL] Re: DUPONT: GRN 000969 Questions
Attachments: Notifier Final Responses to 2021_04_30 GRN 969 Questions May 7 2021.pdf

Follow Up Flag: Follow up
Flag Status: Flagged

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Viebrock,

Please find attached the notifier's responses to the GRN 969 questions. Please don't hesitate to let me know if any other questions come up or if you need any clarification on the attached. Wishing you a nice weekend!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc.
(253) 286-2888
www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Date: Friday, April 30, 2021 at 10:42 AM
To: "jessica@aibmr.com" <jessica@aibmr.com>
Subject: GRN 000969 Questions

Dear Ms. Gruber,

During our review of GRAS Notice No. 000969, we noted questions that need to be addressed. Please find the questions attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Regards,
Lauren

Lauren VieBrock

Regulatory Review Scientist/Microbiology Reviewer

Center for Food Safety and Applied Nutrition

Office of Food Additive Safety

U.S. Food and Drug Administration

Tel: 301-796-7454

lauren.viebrock@fda.hhs.gov





Lauren VieBrock
Regulatory Review Scientist/Microbiology Reviewer
Center for Food Safety and Applied Nutrition
Office of Food Additive Safety
U.S. Food and Drug Administration
Tel: 301-796-7454
lauren.viebrock@fda.hhs.gov

May 7, 2021

Re: Responses to FDA’s GRN 969 Questions

Dear Dr. VieBrock,

Please find responses to FDA’s questions concerning *Bacillus subtilis* Bss-19 (GRN 969) below. FDA’s questions are in BLACK, while the notifier responses are in BLUE:

1. Danisco states that AOAC method 984.27 was used for the determination of arsenic, cadmium and lead content. AOAC method 984.27 is validated for the determination of calcium, copper, iron, magnesium, manganese, phosphorus, potassium, sodium, and zinc in infant formula using ICP-OES. Please clarify what method was used to provide the results in the Table 3 for As, Cd and Pb. **The actual method used for As, Cd, and Pb determination in *Bacillus subtilis* Bss-19 is AOAC 2013.06.**
2. Please provide the specific method for the analysis of mold/yeast in the cited USP41-NF36 compendium. **The actual method used for mold/yeast analysis is FDA BAM Chapter 18. Please see the revised specification table for *Bacillus subtilis* Bss-19 below:**

Tested Parameters	Specification	Method
Viable cell count (CFU/g)	$\geq 2.25 \times 10^{11}$	In-house method
Color ¹	White to cream	Visual Inspection
Form ¹	Freeze-dried powder	Visual Inspection
Heavy Metals²		
Arsenic (ppm)	< 1.0 ppm	AOAC 2013.06
Cadmium (ppm)	< 0.2 ppm	AOAC 2013.06
Mercury (ppm)	< 0.05 ppm	AOAC 2013.06
Lead (ppm)	< 0.5 ppm	AOAC 2013.06

1425 Broadway
Suite 458
Seattle, WA 98122
(253) 286-2888 ph
www.aibmr.com
www.toxicoop.com



AIMMR
Life Sciences, Inc.

Microbiological Tests		
Coliform (CFU/g)	< 10	AOAC 991.14
<i>Escherichia coli</i> (CFU/g)	< 10	AOAC 991.14
<i>Salmonella</i>	Negative in 50 g	AOAC RI-121501
<i>Listeria</i>	Negative in 25 g	FDA BAM Chapter 10
<i>Staphylococcus coag+</i> (CFU/g)	< 10	FDA BAM Chapter 12
<i>B. cereus</i> (CFU/g)	< 10	AOAC 980.31
Molds and Yeast ³	< 100 CFU/g	FDA BAM Chapter 18

Abbreviations: CFU, colony forming unit; AOAC, Association of Official Analytical Chemists; FDA BAM, Food and Drug Administration's Bacteriological Analytical Manual; ppm, parts per million

¹ Internal Specification, not reported on CoA

² Based on annual surveillance testing, not generally reported on CoA

³ Tested on bulk intermediate powder, not generally reported on CoA

3. At the time of the submission of the notice, Danisco stated that stability studies are underway. Please provide results from the stability studies. The results of 24 months of stability testing for *Bacillus subtilis* Bss-19 under three different testing conditions (temperature and relative humidity) are shown below:

Results in CFU/g	Testing Condition	Months								loss after 24 months
		0	1	3	6	9	12	18	24	
Batch 1 (1493413902)	25°C 60% RH	4.30E+11	4.10E+11	5.20E+11	4.60E+11	4.53E+11	5.73E+11	5.30E+11	4.03E+11	6%
Batch 1 (1493413902)	30°C 65% RH	4.30E+11	4.43E+11	5.03E+11	3.53E+11	5.07E+11	4.10E+11	4.30E+11	2.80E+11	35%
Batch 1 (1493413902)	40°C 75% RH	4.30E+11	4.70E+11	4.60E+11	5.40E+11	2.97E+11	2.70E+11	1.53E+11	7.83E+10	82%
Batch 2 (1493438028)	25°C 60% RH	4.30E+11	5.77E+11	4.40E+11	4.90E+11	5.93E+11	5.10E+11	4.70E+11	5.37E+11	-25%
Batch 2 (1493438028)	30°C 65% RH	4.30E+11	4.33E+11	5.10E+11	4.87E+11	4.57E+11	4.27E+11	5.57E+11	2.57E+11	40%
Batch 2 (1493438028)	40°C 75% RH	4.30E+11	4.70E+11	3.87E+11	4.33E+11	2.23E+11	1.36E+11	1.12E+11	7.27E+10	83%
Batch 3 (1493441558)	25°C 60% RH	4.03E+11	4.77E+11	3.90E+11	3.27E+11	3.23E+11	2.93E+11	3.40E+11	3.40E+11	16%
Batch 3 (1493441558)	30°C 65% RH	4.03E+11	4.67E+11	3.80E+11	3.77E+11	3.83E+11	3.73E+11	2.80E+11	2.19E+11	46%
Batch 3 (1493441558)	40°C 75% RH	4.03E+11	4.90E+11	4.27E+11	3.20E+11	1.84E+11	1.31E+11	4.07E+10	4.93E+10	88%

1425 Broadway
Suite 458
Seattle, WA 98122
(253) 286-2888 ph
www.aibmr.com
www.toxicoop.com



Overall, the average loss in the three batches by condition over 24 months are as follows:

- 25°C/60% RH = -1%
- 30°C/65% RH = 40%
- 40°C/75% RH = 84%

4. Please clarify whether the strain has been deposited in a recognized culture collection. The strain has been deposited in the American Type Culture Collection (ATCC) with an ID of “SD-7780”. ATCC confirmed receipt of the strain on May 28th, 2020.

5. Please provide more information on the proportions of spores to vegetative cells in the spore preparation. At the end of the manufacturing process, the spray dried bacteria are heat shocked to kill all non-spore bacteria (~80 °C for 15 minutes). Thus, the final ingredient consists of essentially 100% spores.

6. Please clarify whether or not the intended use in beverages includes intended use in alcoholic beverages. The notifier would like to include alcoholic beverages as an intended use for *Bacillus subtilis* Bss-19. Please let us know if you have any concerns with this use of the ingredient.

Sincerely,



Amy Clewell, ND, DABT
Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc., on behalf of Danisco USA, Inc.

1425 Broadway
Suite 458
Seattle, WA 98122
(253) 286-2888 ph
www.aibmr.com
www.toxicoop.com

Viebrock, Lauren

From: Amy Clewell <amy@aibmr.com>
Sent: Wednesday, September 1, 2021 5:05 PM
To: Viebrock, Lauren
Cc: John Endres; Jared Brodin
Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions
Attachments: Notifier Final Responses to 2021_04_30 GRN 969 Questions Sept 1 2021.pdf

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Viebrock,

I hope that this email finds you well! Please find attached responses to FDA's most recent questions related to GRN 969. Please also don't hesitate to let us know if you need any additional clarifications. If you could acknowledge that this was received, we'd greatly appreciate it. Thank you!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs

AIBMR Life Sciences, Inc.

(253) 286-2888

www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Date: Thursday, August 19, 2021 at 6:47 AM
To: Amy Clewell <amy@aibmr.com>
Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>
Subject: RE: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Dear Dr. Clewell,

During our review of GRAS Notice No. 000969, we noted an additional question that need to be addressed.

-On page 23 of the notice, the notifier states that uses in other foods (in addition to these listed in GRN 000831 and GRN 000905) may be considered more novel and additive with regards to exposure. FDA requests a clarification what is meant by novel and additional uses. Please specify these additional use categories.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Regards,
Lauren

Lauren VieBrock

Regulatory Review Scientist/Microbiology Reviewer

Center for Food Safety and Applied Nutrition
Office of Food Additive Safety
U.S. Food and Drug Administration
Tel: 301-796-7454
lauren.viebrock@fda.hhs.gov



From: Amy Clewell <amy@aibmr.com>
Sent: Wednesday, May 12, 2021 12:30 PM
To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>
Cc: John Endres <john@aibmr.com>; Jared Brodin <Jared@aibmr.com>
Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you Dr. Viebrock!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc.
(253) 286-2888
www.aibmr.com | [@AIBMRInc](https://twitter.com/AIBMRInc)

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Date: Tuesday, May 11, 2021 at 7:58 AM
To: Amy Clewell <amy@aibmr.com>
Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>
Subject: RE: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Dear Dr. Clewell,

Thank you for your responses to our questions regarding GRN 969. This is confirm receipt of the amendment submitted on May 7, 2021.

Regards,
Lauren

From: Amy Clewell <amy@aibmr.com>
Sent: Monday, May 10, 2021 10:42 PM
To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>
Cc: John Endres <john@aibmr.com>; Jared Brodin <Jared@aibmr.com>
Subject: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Viebrock,
I am writing just to make sure that the responses to GRN 969 were received per the email below. Thank you in advance for confirming!

Kind Regards,

Amy Clewell, ND, DABT
Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc.
(253) 286-2888
www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: Amy Clewell <amy@aibmr.com>
Date: Friday, May 7, 2021 at 2:00 PM
To: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>
Subject: Re: DUPONT: GRN 000969 Questions

Dear Dr. Viebrock,

Please find attached the notifier's responses to the GRN 969 questions. Please don't hesitate to let me know if any other questions come up or if you need any clarification on the attached. Wishing you a nice weekend!

Kind Regards,

Amy Clewell, ND, DABT
Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc.
(253) 286-2888
www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>

Date: Friday, April 30, 2021 at 10:42 AM

To: "jessica@aibmr.com" <jessica@aibmr.com>

Subject: GRN 000969 Questions

Dear Ms. Gruber,

During our review of GRAS Notice No. 000969, we noted questions that need to be addressed. Please find the questions attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Regards,
Lauren

Lauren VieBrock

Regulatory Review Scientist/Microbiology Reviewer

Center for Food Safety and Applied Nutrition

Office of Food Additive Safety

U.S. Food and Drug Administration

Tel: 301-796-7454

lauren.viebrock@fda.hhs.gov





Lauren VieBrock
Regulatory Review Scientist/Microbiology Reviewer
Center for Food Safety and Applied Nutrition
Office of Food Additive Safety
U.S. Food and Drug Administration
Tel: 301-796-7454
lauren.viebrock@fda.hhs.gov

September 1, 2021

Re: Responses to FDA's GRN 969 Questions

Dear Dr. VieBrock,

Please find responses to FDA's questions concerning *Bacillus subtilis* Bss-19 (GRN 969) below. FDA's questions are in BLACK, while the notifier responses are in BLUE:

1) On page 23 of the notice, the notifier states that uses in other foods (in addition to these listed in GRN 000831 and GRN 000905) may be considered more novel and additive with regards to exposure. FDA requests a clarification what is meant by novel and additional uses. Please specify these additional use categories. As you are aware, the intended use of *B. subtilis* Bss-19 in GRN 969 is as an ingredient added to foods at a level of up to 1×10^{10} CFU/serving where standards of identity do not preclude such use (note that this use does not including alcoholic beverages—see question 2 below. The GRN also points out that it does not include use in infant formula or in foods that would require additional USDA review). Some general examples were given on page 23 of the notice (“yogurt and other dairy products, soy products, beverages, chewing gum, confectionary, snacks, and other foods”), however the examples were not intended to be all-inclusive.

As noted, the GRN also states that “The addition of Bss-19 to some foods may be substitutive with regard to other GRAS *B. subtilis* strains' intended uses (e.g. GRN 831 and 905), or with regard to traditional uses of *B. subtilis*. However, uses in other foods may be considered more novel and additive with regard to exposure.” This statement was only meant to conservatively point out that while there is a lot of overlap in the intended uses in GRN 969 compared to those in GRNs 831 and 905 as well as traditional uses, there may hypothetically be uses that do not overlap and thus could be considered “additional” (additive) or “novel” versus substitutive between *B. subtilis* strains. To clarify this further, the intended uses stated in GRNs 831 and 905 are reviewed below:

1425 Broadway
Suite 458
Seattle, WA 98122
(253) 286-2888 ph
www.aibmr.com
www.toxicoop.com



- GRN 831 states a large number of uses for its *B. subtilis* strain, but the list appears to be finite (i.e. the list was not just examples, but instead was a full list of uses). The list includes use in baked goods and baking mixes; beverages and beverage bases; breakfast cereals; chewing gum; coffee and tea; condiments and relishes; confections and frostings; dairy product analogs; fats and oils; fruit juices; frozen dairy desserts and mixes; fruit and water ices; gelatins, puddings, and fillings; grain products and pastas; soft/hard candy and cough drops; herbs, seeds, spices, seasonings, blends, extracts, and flavorings; jams and jellies; milk and milk products; nuts and nut products; plant protein products; processed fruits; processed vegetables and vegetable juices; snack foods; soups and soup mixes; sugar; and sweet sauces, toppings, and syrups at levels from 1×10^6 to 1×10^{10} CFU/serving.
- GRN 905 states that its *B. subtilis* strain is intended to be used as an “ingredient in conventional foods at a level of 10^9 CFU/serving”.

Thus, while Bss-19 is a unique strain of *B. subtilis*, the uses of this strain could be substitutive for many of the *B. subtilis* traditional or intended uses from other GRN strains. *B. subtilis* is generally used in some traditional fermented foods as described in GRN 969, and thus use of the Bss-19 strain in such foods may be considered substitutive for use of other *B. subtilis* strains if used in a similar manner. Use of Bss-19 may also be substitutive in various foods with regard to the *B. subtilis* strain from GRN 831 since the addition levels are identical (up to 10^{10} CFU/serving) and because GRN 831 lists a large number of intended use food categories. However, because Bss-19 is intended for use in *any* food (except those categories stipulated above), there may be hypothetical instances where it is added to a food not included in the GRN 831 list.

Similarly, while the *B. subtilis* strain in GRN 905 is intended for use in *any* conventional food, the maximum addition level is slightly lower than the addition level stated for Bss-19 in GRN 969. Thus, while use of the Bss-19 strain in conventional food categories would likely be substitutive to those of the strain in GRN 905, Bss-19 may be added to some foods at a slightly higher addition level per serving than that of the strain in GRN 905 (10^{10} versus 10^9 CFU per serving).

In summary, any hypothetical uses or use levels outside of those covered in the two GRNs listed above or by traditional uses could be considered “additional” or “novel”. However, the notifier does not have any specific “additional” or “novel” uses in mind at this time. We hope this makes sense, and please do not hesitate to let us know if you need any additional clarification.

1425 Broadway
Suite 458
Seattle, WA 98122
(253) 286-2888 ph
www.aibmr.com
www.toxicoop.com



2). Please clarify whether or not the intended use in beverages includes intended use in alcoholic beverages. The notifier would like to withdraw “alcoholic beverages” as an intended use for *Bacillus subtilis* Bss-19.

Sincerely,



Amy Clewell, ND, DABT
Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc., on behalf of Danisco USA, Inc.

1425 Broadway
Suite 458
Seattle, WA 98122
(253) 286-2888 ph
www.aibmr.com
www.toxicoop.com

Viebrock, Lauren

From: Amy Clewell <amy@aibmr.com>
Sent: Monday, September 27, 2021 9:36 AM
To: Viebrock, Lauren
Cc: John Endres; Jared Brodin; West-Barnette, Shayla
Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Lauren and Shayla,

We communicated with the notifier regarding this question. The Bss-19 ingredient is only spray-dried. We apologize for the mention of freeze-drying in the submission. Dupont has other strains that are freeze-dried and this appears to be a typo related to that. Any mention of freeze-drying should be replaced with spray-drying.

Please let us know if you have any other questions or need any other information in this regard. Thank you!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs

AIBMR Life Sciences, Inc.

(253) 286-2888

www.aibmr.com | [@AIBMRInc](https://twitter.com/AIBMRInc)

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Date: Friday, September 24, 2021 at 6:18 PM
To: Amy Clewell <amy@aibmr.com>
Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>, "West-Barnette, Shayla" <Shayla.WestBarnette@fda.hhs.gov>
Subject: RE: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Hi Amy,

Thank you for the update. We look forward to receiving the response.

In the event that I am on leave when your response is submitted, please also include my colleague Dr. Shayla West-Barnette (whose contact information is copied on this email) and she will then become the Regulatory Review Scientist and point of contact for your submission moving forward.

Best,
Lauren

From: Amy Clewell <amy@aibmr.com>
Sent: Thursday, September 23, 2021 3:55 PM
To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>
Cc: John Endres <john@aibmr.com>; Jared Brodin <Jared@aibmr.com>
Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Lauren,
I just wanted to let you know that this question was received and I'm seeking feedback from Dupont about an answer. I'll send it to you as soon as we receive it.
Thanks!

Kind Regards,

Amy Clewell, ND, DABT
Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc.
(253) 286-2888
www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Date: Wednesday, September 22, 2021 at 6:26 AM
To: Amy Clewell <amy@aibmr.com>
Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>
Subject: RE: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Hi Amy,

Thank you for confirming the notifier name.

One additional question on GRN 969. The ingredient description states it is a freeze-dried powder, while the manufacturing section describes the ingredient as spray-dried. Can you please clarify whether the ingredient is spray- or freeze-dried. Thank you.

Best,
Lauren

From: Amy Clewell <amy@aibmr.com>
Sent: Monday, September 13, 2021 9:53 PM
To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>
Cc: John Endres <john@aibmr.com>; Jared Brodin <Jared@aibmr.com>
Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hello again Lauren,

Our main contact for the project (i.e. the Notifier) responded as follows:

"Danisco USA, Inc. is still our legal entity, I think it would make most sense to have FDA continue to address letters to this company name."

Thanks very much for checking in on this, and let us know if there is anything else that you need!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs

AIBMR Life Sciences, Inc.

(253) 286-2888

www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: Amy Clewell <amy@aibmr.com>

Date: Monday, September 13, 2021 at 8:56 AM

To: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>

Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>

Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Good morning Lauren,

This is a great question! I will check with the client (notifier) and get back to you ASAP.

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs

AIBMR Life Sciences, Inc.

(253) 286-2888

www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>

Date: Monday, September 13, 2021 at 7:59 AM

To: Amy Clewell <amy@aibmr.com>

Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>

Subject: RE: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Hi Amy,

Thank you for your response. The notifier is written as "Danisco USA, Inc" in the submission. With the recent organizational changes at the company, is that how the notifier should still be addressed in our correspondences?

Thanks,
Lauren

From: Amy Clewell <amy@aibmr.com>
Sent: Wednesday, September 1, 2021 5:05 PM
To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>
Cc: John Endres <john@aibmr.com>; Jared Brodin <Jared@aibmr.com>
Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Viebrock,
I hope that this email finds you well! Please find attached responses to FDA's most recent questions related to GRN 969. Please also don't hesitate to let us know if you need any additional clarifications. If you could acknowledge that this was received, we'd greatly appreciate it. Thank you!

Kind Regards,

Amy Clewell, ND, DABT
Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc.
(253) 286-2888
www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Date: Thursday, August 19, 2021 at 6:47 AM
To: Amy Clewell <amy@aibmr.com>
Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>
Subject: RE: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Dear Dr. Clewell,

During our review of GRAS Notice No. 000969, we noted an additional question that need to be addressed.

-On page 23 of the notice, the notifier states that uses in other foods (in addition to these listed in GRN 000831 and GRN 000905) may be considered more novel and additive with regards to exposure. FDA requests a clarification what is meant by novel and additional uses. Please specify these additional use categories.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Regards,
Lauren

Lauren VieBrock

Regulatory Review Scientist/Microbiology Reviewer

Center for Food Safety and Applied Nutrition
Office of Food Additive Safety
U.S. Food and Drug Administration
Tel: 301-796-7454
lauren.viebrock@fda.hhs.gov



From: Amy Clewell <amy@aibmr.com>
Sent: Wednesday, May 12, 2021 12:30 PM
To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>
Cc: John Endres <john@aibmr.com>; Jared Brodin <Jared@aibmr.com>
Subject: Re: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you Dr. Viebrock!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs
AIBMR Life Sciences, Inc.
(253) 286-2888
www.aibmr.com | [@AIBMRInc](https://twitter.com/AIBMRInc)

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>
Date: Tuesday, May 11, 2021 at 7:58 AM
To: Amy Clewell <amy@aibmr.com>

Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>

Subject: RE: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

Dear Dr. Clewell,

Thank you for your responses to our questions regarding GRN 969. This is confirm receipt of the amendment submitted on May 7, 2021.

Regards,
Lauren

From: Amy Clewell <amy@aibmr.com>

Sent: Monday, May 10, 2021 10:42 PM

To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>

Cc: John Endres <john@aibmr.com>; Jared Brodin <Jared@aibmr.com>

Subject: [EXTERNAL] Re: DUPONT: GRN 000969 Questions

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Viebrock,

I am writing just to make sure that the responses to GRN 969 were received per the email below. Thank you in advance for confirming!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs

AIBMR Life Sciences, Inc.

(253) 286-2888

www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: Amy Clewell <amy@aibmr.com>

Date: Friday, May 7, 2021 at 2:00 PM

To: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>

Cc: John Endres <john@aibmr.com>, Jared Brodin <Jared@aibmr.com>

Subject: Re: DUPONT: GRN 000969 Questions

Dear Dr. Viebrock,

Please find attached the notifier's responses to the GRN 969 questions. Please don't hesitate to let me know if any other questions come up or if you need any clarification on the attached. Wishing you a nice weekend!

Kind Regards,

Amy Clewell, ND, DABT

Vice President, Scientific and Regulatory Affairs

AIBMR Life Sciences, Inc.

(253) 286-2888

www.aibmr.com | @AIBMRInc

The information contained in this transmission may be legally privileged and confidential information intended only for the use of the intended recipient. If you are not the intended recipient, the review, dissemination, distribution, copying, or printing of this transmission is strictly prohibited. If you have received this message in error, please notify me immediately.

From: "Viebrock, Lauren" <Lauren.Viebrock@fda.hhs.gov>

Date: Friday, April 30, 2021 at 10:42 AM

To: "jessica@aibmr.com" <jessica@aibmr.com>

Subject: GRN 000969 Questions

Dear Ms. Gruber,

During our review of GRAS Notice No. 000969, we noted questions that need to be addressed. Please find the questions attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Regards,
Lauren

Lauren VieBrock

Regulatory Review Scientist/Microbiology Reviewer

Center for Food Safety and Applied Nutrition

Office of Food Additive Safety

U.S. Food and Drug Administration

Tel: 301-796-7454

lauren.viebrock@fda.hhs.gov



From: [Victoria](#)
To: [Viebrock, Lauren](#)
Cc: [West-Barnette, Shayla](#)
Subject: RE: [EXTERNAL] RE: GRN 957
Date: Wednesday, October 6, 2021 9:07:04 AM
Attachments: [image001.png](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Lauren, the 3mg level that manufacture uses is their maximum level so anything under that would be detected. They have told me that they will work according the FDA U.S. metal limits and change the upper limit for lead to 0.5 mg/kg.

Thank you

Victoria Davis

Prozure

(561)926.2723

This email (and any attachments) is only intended for the use of the person or entity to which it is addressed, and may contain information that is privileged and confidential. You, the recipient, are obligated to maintain it in a safe, secure and confidential manner. Unauthorized disclosure or failure to maintain confidentiality may subject you to federal and state penalties. If you are not the intended recipient, please immediately notify us by return email, and delete this message from your computer.

From: Viebrock, Lauren [mailto:Lauren.Viebrock@fda.hhs.gov]
Sent: Tuesday, September 28, 2021 3:22 PM
To: Victoria
Cc: West-Barnette, Shayla
Subject: RE: [EXTERNAL] RE: GRN 957

Hi Victoria,

Please find our additional question for GRN 957 below.

In response to questions raised during our review of your notice, you confirmed that there was no expectation that heavy metal contaminants, including lead, are present or detectable in your *Lactobacillus johnsonii* ingredient. The specified limit for lead presented in your GRAS notice is up to 3 mg/kg and the results of batch analyses were reported in certificates of analysis as <3 mg/kg, zero, or 'none detected.' Although specification limits for contaminants are typically set a level higher than the limits of the methods used for their detection, we note that the limit of 3 mg/kg that you specified for lead is relatively high given the method used for its detection (ICP/MS), which would be expected to have a significantly lower limit of quantitation. Because lead is not expected to be present at quantifiable levels, a limit of 3 mg/kg may be unnecessarily high. In order to provide

assurance that lead will be present in your ingredient at minimal levels, we request that you reduce the specified limit for lead to a level that more closely reflects the detection limit of the analytical method, which would be expected to be much lower than 3 mg/kg.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options.

If you have questions or need further clarification, please feel free to contact me or Shayla. Thank you in advance for your attention to our comment.

Regards,
Lauren

From: Victoria <vdavis@prozure.net>
Sent: Sunday, September 26, 2021 6:53 PM
To: Viebrock, Lauren <Lauren.Viebrock@fda.hhs.gov>
Cc: West-Barnette, Shayla <Shayla.WestBarnette@fda.hhs.gov>
Subject: [EXTERNAL] RE: GRN 957

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you Lauren

Victoria Davis

Prozure

(561)926.2723

This email (and any attachments) is only intended for the use of the person or entity to which it is addressed, and may contain information that is privileged and confidential. You, the recipient, are obligated to maintain it in a safe, secure and confidential manner. Unauthorized disclosure or failure to maintain confidentiality may subject you to federal and state penalties. If you are not the intended recipient, please immediately notify us by return email, and delete this message from your computer.

From: Viebrock, Lauren [<mailto:Lauren.Viebrock@fda.hhs.gov>]
Sent: Friday, September 24, 2021 9:12 PM
To: Victoria
Cc: West-Barnette, Shayla
Subject: GRN 957

Hi Victoria,

Thank you and Michael for speaking with us regarding the lead specification limit provided in GRN 957. We will be in touch shortly with the written follow up question. The email may come from me,

but in the event that I am on leave at that time, it will come from my colleague Dr. Shayla West-Barnette (whose contact information is copied on this email) and she will then become the Regulatory Review Scientist and point of contact for your submission moving forward.

Best,
Lauren

Lauren VieBrock

Regulatory Review Scientist/Microbiology Reviewer

Center for Food Safety and Applied Nutrition

Office of Food Additive Safety

U.S. Food and Drug Administration

Tel: 301-796-7454

lauren.viebrock@fda.hhs.gov

